Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment-Reference-Cited by-同舟云学术

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment

Published:2018-11-12 Issue: Volume:9 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Malinowski Krzysztof Piotr,Kawalec Paweł,Trabka Wojciech,Sowada Christoph,Pilc Andrzej

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference26 articles.

1. Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?;Adkins;Clinicoecon. Outcomes Res.,2017

2. 2018

3. 2006

4. Critical assessment of belgian reimbursement dossiers of orphan drugs;Denis;Pharmacoeconomics,2011

5. Generic substitution of orphan drugs for the treatment of rare diseases: exploring the potential challenges;Di Paolo;Drugs,2018

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries;Frontiers in Pharmacology;2024-03-08

2. The impact of level of documentation on the accessibility and affordability of new drugs in Norway;Frontiers in Pharmacology;2024-02-14

3. Development of medicines for rare diseases and inborn errors of metabolism: Toward novel public–private partnerships;Journal of Inherited Metabolic Disease;2023-04

4. Access to medicines for rare diseases: A European regulatory roadmap for academia;Frontiers in Pharmacology;2023-02-28

5. Improving Access to Rare Disease Treatments: Subsidy, Pricing, and Payment Schemes;Management Science;2022-12-15